Literature DB >> 29088406

Dengvaxia Efficacy Dependency on Serostatus: A Closer Look at More Recent Data.

Maíra Aguiar1, Nico Stollenwerk2.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29088406     DOI： 10.1093/cid/cix882

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  10 in total

1.  Reply to Aguiar and Stollenwerk.

Authors:  Yang Yang; Ya Meng; M Elizabeth Halloran; Ira M Longini
Journal:  Clin Infect Dis       Date:  2018-02-01       Impact factor: 9.079

2.  Modeling the initial phase of COVID-19 epidemic: The role of age and disease severity in the Basque Country, Spain.

Authors:  Akhil Kumar Srivasrav; Nico Stollenwerk; Joseba Bidaurrazaga Van-Dierdonck; Javier Mar; Oliver Ibarrondo; Maíra Aguiar
Journal:  PLoS One       Date:  2022-07-13       Impact factor: 3.752

3.  The role of mild and asymptomatic infections on COVID-19 vaccines performance: A modeling study.

Authors:  Maíra Aguiar; Joseba Bidaurrazaga Van-Dierdonck; Javier Mar; Nico Stollenwerk
Journal:  J Adv Res       Date:  2021-11-16       Impact factor: 12.822

4.  The Optimal Age of Vaccination Against Dengue with an Age-Dependent Biting Rate with Application to Brazil.

Authors:  Sandra B Maier; Eduardo Massad; Marcos Amaku; Marcelo N Burattini; David Greenhalgh
Journal:  Bull Math Biol       Date:  2020-01-14       Impact factor: 1.758

Review 5.  Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines.

Authors:  Jue Hou; Weijian Ye; Jianzhu Chen
Journal:  Front Immunol       Date:  2022-02-24       Impact factor: 7.561

6.  Combination of E- and NS1-Derived DNA Vaccines: The Immune Response and Protection Elicited in Mice against DENV2.

Authors:  Paolla Beatriz A Pinto; Tamiris A C Barros; Lauro M Lima; Agatha R Pacheco; Maysa L Assis; Bernardo A S Pereira; Antônio J S Gonçalves; Adriana S Azevedo; Ana Gisele C Neves-Ferreira; Simone M Costa; Ada M B Alves
Journal:  Viruses       Date:  2022-06-30       Impact factor: 5.818

7.  A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies.

Authors:  Niraj Mishra; Robbert Boudewijns; Michael Alexander Schmid; Rafael Elias Marques; Sapna Sharma; Johan Neyts; Kai Dallmeier
Journal:  mBio       Date:  2020-04-07       Impact factor: 7.867

8.  The Impact of Serotype Cross-Protection on Vaccine Trials: DENVax as a Case Study.

Authors:  Maíra Aguiar; Nico Stollenwerk
Journal:  Vaccines (Basel)       Date:  2020-11-12

Review 9.  Pathogen Dose in Animal Models of Hemorrhagic Fever Virus Infections and the Potential Impact on Studies of the Immune Response.

Authors:  Bryce M Warner
Journal:  Pathogens       Date:  2021-03-01

10.  Neutralization of Dengue Virus Serotypes by Sera from Dengue-Infected Individuals Is Preferentially Directed to Heterologous Serotypes and Not against the Autologous Serotype Present in Acute Infection.

Authors:  Heidi Auerswald; Simone Kann; Leonard Klepsch; Janne Hülsemann; Ines Rudnik; Sebastian Schreiber; Philippe Buchy; Michael Schreiber
Journal:  Viruses       Date:  2021-09-29       Impact factor: 5.048
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.